Jisanda is a pan genotype oral antiviral drug for hepatitis C, with clear standard usage and dosage, fixed treatment course, and minimal impact...
Jisanda is a core drug for the treatment of hepatitis C, but extra caution should be exercised in specific combination therapy or postoperative...
Epclusa is a pan genotype antiviral drug for hepatitis C, but it is not suitable for all patients. Severe liver injury patients may have an inc...
Jisanda is a commonly used medication for the treatment of chronic hepatitis C. Some patients may experience headaches, fatigue, or nausea duri...
Baricitinib is an oral JAK inhibitor used to treat autoimmune diseases. Standardized medication is the key to ensuring efficacy and safety, and...
Baricitinib is a JAK inhibitor, and when treating inflammatory diseases, special attention should be paid to risks such as infection, thrombosi...
Baricitinib is a JAK inhibitor with clear contraindications for use in specific patient populations. The following three groups of people need ...
Baricitinib may cause side effects such as upper respiratory tract infections, nausea, and headaches during treatment. Scientific management of...
Regorafenib is an oral multi-target inhibitor, and its efficacy relies on precise dosage execution and rigorous adverse event monitoring. The f...
The medication safety of regorafenib relies on active monitoring and immediate intervention of the three core adverse reactions. The following ...